PMID- 31208922
OWN - NLM
STAT- MEDLINE
DCOM- 20210722
LR  - 20210722
IS  - 2210-741X (Electronic)
IS  - 2210-7401 (Linking)
VI  - 44
IP  - 2
DP  - 2020 Apr
TI  - The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment 
      of previously treated, advanced gastric or gastro-oesophageal junction cancer: A 
      meta-analysis of prospective clinical trials.
PG  - 211-222
LID - S2210-7401(19)30104-4 [pii]
LID - 10.1016/j.clinre.2019.05.007 [doi]
AB  - INTRODUCTION: So far, anti-PD-1/anti-PD-L1 antibody therapy is reportedly in 
      treating gastric cancer or gastro-oesophageal junction cancer (GC/GEJC) in a 
      number of clinical trials. Based on this, we conducted current meta-analysis to 
      assess the safety and efficacy of anti-PD-1/anti-PD-L1 antibody for previously 
      treated advanced GC/GEJC patients. METHODS: We searched five electronic databases 
      for eligible records. Outcomes were presented and analyzed by objective response 
      rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall 
      survival (OS) and adverse effects (AEs). RESULTS: Nine records involving 1388 
      participants were selected in our study. The pooled ORR, DCR, OS rate (6 month), 
      PFS rate (6 month), OS rate (12 month) and PFS rate (12 month) were 10% (95% 
      confidence interval [CI]: 6%-14%), 32% (95%CI: 25%-38%), 52% (95%CI: 44%-61%), 
      18% (95%CI: 13%-24%), 40% (95%CI: 31%-48%) and 8% (95%CI: 5%-10%), respectively. 
      Meanwhile, grade>/=3 AEs rate was 12% (95% CI: 10%-15%). Programmed death ligand 1 
      (PD-L1) positive cases had higher rate of ORR (odds ratio [OR]: 3.75, 95%CI: 
      2.09-6.74, P=0.58) compared with negative cases. CONCLUSION: The results 
      indicated that anti-PD-1/anti-PD-L1 antibody therapy has an effectual anti-tumor 
      activity and controllable AEs in advanced GC/GEJC patients. Furthermore, 
      overexpression of PD-L1 in advanced GC/GEJC patients had better ORR from 
      anti-PD-1/anti-PD-L1 antibody therapy (PROSPERO registration number: 
      CRD42018116480).
CI  - Copyright (c) 2019 Elsevier Masson SAS. All rights reserved.
FAU - Ni, Xiaofei
AU  - Ni X
AD  - Department of Gastrointestinal Surgery, First Hospital of Jilin University, 71, 
      Xinmin Street, Chaoyang District, 130021 Changchun, China. Electronic address: 
      nixiaofei84@hotmail.com.
FAU - Xing, Yanpeng
AU  - Xing Y
AD  - Department of Gastrointestinal Surgery, First Hospital of Jilin University, 71, 
      Xinmin Street, Chaoyang District, 130021 Changchun, China. Electronic address: 
      xingyanpengjdyy1@hotmail.com.
FAU - Sun, Xuan
AU  - Sun X
AD  - Department of Gastrointestinal Surgery, First Hospital of Jilin University, 71, 
      Xinmin Street, Chaoyang District, 130021 Changchun, China. Electronic address: 
      sunxuan23@hotmail.com.
FAU - Suo, Jian
AU  - Suo J
AD  - Department of Gastrointestinal Surgery, First Hospital of Jilin University, 71, 
      Xinmin Street, Chaoyang District, 130021 Changchun, China. Electronic address: 
      suojian24@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20190614
PL  - France
TA  - Clin Res Hepatol Gastroenterol
JT  - Clinics and research in hepatology and gastroenterology
JID - 101553659
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Antineoplastic Agents, Immunological/adverse effects/*therapeutic use
MH  - B7-H1 Antigen/immunology
MH  - Clinical Trials as Topic
MH  - Esophageal Neoplasms/*drug therapy/immunology/pathology
MH  - *Esophagogastric Junction
MH  - Humans
MH  - Immunotherapy/adverse effects
MH  - Neoplasm Staging
MH  - Programmed Cell Death 1 Receptor/immunology
MH  - Prospective Studies
MH  - Retreatment
MH  - Stomach Neoplasms/*drug therapy/immunology/pathology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Anti-PD-1/anti-PD-L1 antibody
OT  - Gastric cancer
OT  - Gastro-oesophageal junction cancer
OT  - Meta-analysis
EDAT- 2019/06/19 06:00
MHDA- 2021/07/23 06:00
CRDT- 2019/06/19 06:00
PHST- 2019/01/05 00:00 [received]
PHST- 2019/04/17 00:00 [revised]
PHST- 2019/05/12 00:00 [accepted]
PHST- 2019/06/19 06:00 [pubmed]
PHST- 2021/07/23 06:00 [medline]
PHST- 2019/06/19 06:00 [entrez]
AID - S2210-7401(19)30104-4 [pii]
AID - 10.1016/j.clinre.2019.05.007 [doi]
PST - ppublish
SO  - Clin Res Hepatol Gastroenterol. 2020 Apr;44(2):211-222. doi: 
      10.1016/j.clinre.2019.05.007. Epub 2019 Jun 14.